Robert Stagg

4.3k total citations
61 papers, 3.3k citations indexed

About

Robert Stagg is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Robert Stagg has authored 61 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 15 papers in Molecular Biology. Recurrent topics in Robert Stagg's work include Cancer Cells and Metastasis (15 papers), Pancreatic and Hepatic Oncology Research (11 papers) and Lung Cancer Treatments and Mutations (11 papers). Robert Stagg is often cited by papers focused on Cancer Cells and Metastasis (15 papers), Pancreatic and Hepatic Oncology Research (11 papers) and Lung Cancer Treatments and Mutations (11 papers). Robert Stagg collaborates with scholars based in United States, Australia and New Zealand. Robert Stagg's co-authors include B.J. Lewis, Mark Kaminski, Richard L. Wahl, George F. Tidmarsh, Ann M. Kapoun, David C. Hohn, Anthony A. Rayner, Andrew D. Zelenetz, Mansoor N. Saleh and Susan J. Knox and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Internal Medicine.

In The Last Decade

Robert Stagg

61 papers receiving 3.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Stagg United States	24	1.4k	987	947	824	705	61	3.3k
Daniel H. Ahn United States	31	2.0k 1.4×	520 0.5×	554 0.6×	803 1.0×	283 0.4×	153	3.7k
R. Lamerz Germany	29	1.9k 1.4×	762 0.8×	403 0.4×	1.4k 1.7×	222 0.3×	107	4.0k
Svend Aage Engelholm Denmark	29	812 0.6×	234 0.2×	652 0.7×	397 0.5×	242 0.3×	94	3.3k
J Klein United States	24	612 0.4×	307 0.3×	584 0.6×	733 0.9×	262 0.4×	85	2.1k
Satoru Iwasa Japan	30	2.7k 2.0×	357 0.4×	478 0.5×	782 0.9×	205 0.3×	255	4.4k
Thomas J. Ervin United States	27	1.3k 1.0×	474 0.5×	179 0.2×	760 0.9×	235 0.3×	81	2.9k
Barrett H. Childs United States	20	2.1k 1.5×	731 0.7×	159 0.2×	572 0.7×	192 0.3×	101	3.3k
Jacob D. Bitran United States	32	1.5k 1.1×	578 0.6×	275 0.3×	462 0.6×	94 0.1×	138	3.0k
J. Mezger Germany	18	1.9k 1.4×	451 0.5×	155 0.2×	746 0.9×	183 0.3×	53	3.4k
Amrita Krishnan United States	35	2.8k 2.0×	1.1k 1.1×	612 0.6×	2.2k 2.7×	117 0.2×	198	5.6k

Countries citing papers authored by Robert Stagg

Since Specialization

Citations

This map shows the geographic impact of Robert Stagg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Stagg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Stagg more than expected).

Fields of papers citing papers by Robert Stagg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Stagg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Stagg. The network helps show where Robert Stagg may publish in the future.

Co-authorship network of co-authors of Robert Stagg

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Stagg. A scholar is included among the top collaborators of Robert Stagg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Stagg. Robert Stagg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yarchoan, Mark, John D. Powderly, Bruno R. Bastos, et al.. (2024). First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer Research Communications. 4(4). 1100–1110. 11 indexed citations

Fu, Siqing, Bradley R. Corr, Kerry Culm-Merdek, et al.. (2022). Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Journal of Clinical Oncology. 40(23). 2568–2577. 36 indexed citations

Dotan, Efrat, Dana B. Cardin, Heinz‐Josef Lenz, et al.. (2020). Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. Clinical Cancer Research. 26(20). 5348–5357. 59 indexed citations

Coleman, Robert L., Robert A. Burger, Graziela Zibetti Dal Molin, et al.. (2020). Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial. Gynecologic Oncology. 157(2). 386–391. 33 indexed citations

Moore, Kathleen N., Robert A. Burger, Graziela Zibetti Dal Molin, et al.. (2020). Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer (EOC): The SIERRA multi-institutional open-label phase Ib trial. Gynecologic Oncology. 159. 14–14. 1 indexed citations

Moore, Kathleen N., Camille C. Gunderson, Paul Sabbatini, et al.. (2019). A phase 1b dose escalation study of ipafricept (OMP 54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecologic Oncology. 154(2). 294–301. 79 indexed citations

Jimeno, Antonio, Kathleen N. Moore, Michael S. Gordon, et al.. (2018). A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. Investigational New Drugs. 37(3). 461–472. 61 indexed citations

Smith, David C., Rashmi Chugh, Amita Patnaik, et al.. (2018). A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors. Investigational New Drugs. 37(4). 722–730. 58 indexed citations

Gracián, Antonio Cubillo, Andrew Dean, Andrés Muñoz, et al.. (2017). YOSEMITE: A 3 arm double-blind randomized phase 2 study of gemcitabine, paclitaxel protein-bound particles for injectable suspension, and placebo (GAP) versus gemcitabine, paclitaxel protein-bound particles for injectable suspension and either 1 or 2 truncated courses of demcizumab (GAD). Annals of Oncology. 28. v211–v211. 22 indexed citations

10.

McKeage, Mark J., Dusan Kotasek, Ben Markman, et al.. (2017). Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC. Targeted Oncology. 13(1). 89–98. 57 indexed citations

11.

Smith, David C., Peter D. Eisenberg, Georgy M. Manikhas, et al.. (2014). A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors. Clinical Cancer Research. 20(24). 6295–6303. 123 indexed citations

12.

Smith, David C., Michael S. Gordon, Wells A. Messersmith, et al.. (2013). Abstract B79: A first-in-human Phase 1 study of anti-cancer stem cell (CSC) agent OMP-54F28 (FZD8-Fc) targeting the WNT pathway in patients with advanced solid tumors.. Molecular Cancer Therapeutics. 12(11_Supplement). B79–B79. 16 indexed citations

13.

Leonard, J.P., JM Vose, John Radford, et al.. (2000). Iodine I 131 tositumomab for patients with low-grade or transformed low-grade NHL: Complete response data.. Blood. 96. 9 indexed citations

14.

Lalezari, Jacob, Gary N. Holland, Françoise Kramer, et al.. (1998). Randomized, Controlled Study of the Safety and Efficacy of Intravenous Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 17(4). 339–344. 72 indexed citations

15.

Lalezari, Jacob, Robert Stagg, Howard S. Jaffe, Michael J. M. Hitchcock, & William Drew. (1996). A Preclinical and Clinical Overview of the Nucleotide-Based Antiviral Agent Cidofovir (HPMPC). Advances in experimental medicine and biology. 394. 105–115. 21 indexed citations

16.

Small, Eric J., John Frye, Mary Wilkinson, et al.. (1994). A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma. Cancer. 73(11). 2803–2807. 2 indexed citations

17.

Frye, John, Alan P. Venook, James W. Ostroff, et al.. (1992). Hepatic intra-arterial methylene blue injection during endoscopy: a method of detecting gastroduodenal misperfusion in patients receiving hepatic intra-arterial chemotherapy via an implanted pump. Gastrointestinal Endoscopy. 38(1). 52–54. 7 indexed citations

18.

Stagg, Robert, Alan P. Venook, Judy L. Chase, et al.. (1991). Alternating Hepatic Intra-Arterial Floxuridine and Fluorouracil: A Less Toxic Regimen for Treatment of Liver Metastases From Colorectal Cancer. JNCI Journal of the National Cancer Institute. 83(6). 423–428. 67 indexed citations

19.

Venook, Alan P., Robert Stagg, B.J. Lewis, et al.. (1990). Chemoembolization for hepatocellular carcinoma.. Journal of Clinical Oncology. 8(6). 1108–1114. 124 indexed citations

20.

Hohn, David C., Robert Stagg, Michael Friedman, et al.. (1989). A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial.. Journal of Clinical Oncology. 7(11). 1646–1654. 349 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact